Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus()

OBJECTIVE: To compare the efficacy and safety of the once-daily prandial glucagon-like peptide-1 receptor agonist lixisenatide with the dipeptidyl peptidase-4 inhibitor sitagliptin in patients aged <50 years affected by obesity and type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: This was...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Gaal, Luc, Souhami, Elisabeth, Zhou, Tianyue, Aronson, Ronnie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685032/
https://www.ncbi.nlm.nih.gov/pubmed/29159080
http://dx.doi.org/10.1016/j.jcte.2014.03.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685032/
https://www.ncbi.nlm.nih.gov/pubmed/29159080
http://dx.doi.org/10.1016/j.jcte.2014.03.001

Ejemplares similares